From: HPV Status and second primary tumours in Oropharyngeal Squamous Cell Carcinoma
 |  | All patients (N= 406) | p16 status available (N = 199) | |||
---|---|---|---|---|---|---|
 |  |  |  | p16 + (N=118) | p16 - (N=81) | p-value |
Average age |  | 59.1 | ±10.9 | 55.9 | 60.7 | 0.003* |
Sex | Male | 327 | 79.8% | 86.6% | 76.3% | 0.047* |
 | Female | 83 | 20.2% |  |  |  |
Smokers | Â | 281 | 68.5% | 63.5% | 86.8% | 0.0008* |
Stage | IV | 308 | 78.8% | 75.6% | 80.0% | 0.49 |
 | III | 58 | 14.2% | 18.5% | 11.3% | 0.23 |
 | II | 26 | 6.3% | 2.5% | 3.7% | 0.68 |
 | I | 14 | 3.4% | 1.7% | 2.5% | 0.99 |
Index tumour location | Tonsils | 213 | 68.7% | Â | Â | Â |
 | Base of the tongue | 90 | 29.0% |  |  |  |
 | Oropharynx NOS | 15 | 4.8% |  |  |  |
 | Soft palate | 18 | 5.8% |  |  |  |
 | Pharyngeal walls | 15 | 4.8% |  |  |  |
Treatment | Surgery+ChemoRT | 143 | 34.9% | Â | Â | Â |
 | ChemoRT | 216 | 52.7% |  |  |  |
 | Palliative | 16 | 3.9% |  |  |  |
 | Salvage surgery | 11 | 2.7% |  |  |  |
 | No treatment | 21 | 5.1% |  |  |  |
Follow-up (years) |  | 3.9 | ± 1.0 | 3.9 | 3.9 | 0.98 |